Hence, as with radiosensitisation, this is less effective when

cells are hypoxic. One class of platinum complexes which do not appear to rely on oxygen for activity are PtIV diazides. Dihydroxidodiam(m)ine platinum(IV) diazido complexes (e.g. 59 and 60, Figure 4f) are relatively inert in the dark and importantly are not readily reduced by the thiol tri-peptide glutathione, present in most cells at millimolar concentrations. These PtIV complexes possess intense ligan-(azide)-to-PtIV charge-transfer bands suitable for photoactivation. The excited states (which are populated in femto/pico-seconds) can have different geometries including lengthened and weakened Pt ligand bonds [57]. Interestingly, the trans diam(m)ine diazido complexes (60) appear to be more effective as photoactivatable anticancer agents than the cis isomers [ 58]. These complexes are also more effective than cisplatin LY2157299 cost when used under conditions appropriate for clinical phototherapeutic drugs (short treatment times and short irradiation times). Introduction of pyridine ligands instead of ammonia leads to a marked increase in potency and activity at longer wavelengths (61). For example, the trans di-pyridine complex 62 is active

with UVA, blue and green light against a range of cancer cells at low micromolar doses [ 59•]. Longer wavelengths are of special interest because PF-01367338 clinical trial they penetrate more deeply into tissue than short wavelengths. Activating platinum complexes which do not possess long wavelength absorption bands is possible using two photons of red light as fast laser pulses [ 60]. The activity of the complex trans,trans,trans-[Pt(N3)2(OH)2(NH3)(pyridine)] (62) towards oesophageal cancer is enhanced in vivo when irradiated with blue light [ 61•]. The mechanism of action appears distinct ADAMTS5 from that of conventional platinum drugs such as cisplatin. One route of photodecomposition involves two one-electron transfers from the azido ligands generating N2 and PtII

( Figure 4h) which can then form DNA lesions. These lesions can be interstrand (e.g. trans bis-guanine) and different from those formed by cisplatin. Recent work suggests that there may be a role for the released azidyl radicals in the mechanism of action. Such radicals can be readily trapped and characterised by EPR and quenched by the amino acid tryptophan which can protect cancer cells in vitro [ 62•]. Furthermore, Pracharova et al. assessed the importance of DNA binding for the cytotoxicity induced by photoactivated 62. Major DNA adducts of photoactivated 62 are able to stall RNA polymerase II more efficiently than cisplatin, suggesting that transcription inhibition may contribute to the cytotoxicity of photoactivated PtIV complexes [ 63].